학술논문

The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
Document Type
Article
Source
Nature Communications; 2/3/2024, Vol. 15 Issue 1, p1-9, 9p
Subject
PACLITAXEL
TRIPLE-negative breast cancer
BISPECIFIC antibodies
PROGRESSION-free survival
PROGRAMMED death-ligand 1
WOMEN patients
Language
ISSN
20411723
Abstract
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)